Entera Bio Ltd. (ENTX) IPO Opens 9% Lower

Today's IPO for Entera Bio Ltd. (NASDAQ: ENTX) opened for trading at $7.30 after pricing 1,400,000 units, with each unit consisting of one ordinary share and one warrant to purchase 0.5 of an ordinary share, at a combined price of $8.00 per unit.

The Company has granted a 30 day overallotment option to the underwriters to purchase up to 210,000 additional ordinary shares and/or 210,000 additional warrants to purchase up to a total of 105,000 ordinary share.

Maxim Group LLC is acting as sole book-running manager and Joseph Gunnar & Co. is acting a co-manager for the offering.

Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. The Company is initially applying its technology to develop an oral formulation of parathyroid hormone (PTH) for hypoparathyroidism (EB612) and osteoporosis (EB613).

You May Also Be Interested In

• CopperTech Metals launches IPO roadshow on NYSE at $16-$18 per share
• Student Living EduVation files for 6.25M share Nasdaq IPO at $4-$6 per share
• Gores Holdings XI prices $312M IPO on Nasdaq